A股異動 | 影視傳媒股普漲 2022年電影暑期檔票房成績亮眼
格隆匯9月2日丨影視傳媒股普漲,歡瑞世紀、奧飛娛樂漲停,鼎龍文化漲8%,幸福藍海、捷成股份、華誼兄弟、上海電影、浙江影業、橫店影視漲2%。截至8月31日24時數據顯示,2022年電影暑期檔(6月1日至8月31日,共計92天)總票房近92億元,以平均每天1億元的成績,為電影市場復甦注入強勁動力。IMAX中國公佈2022年暑期檔IMAX總票房達到3.03億元,同比增長34%。與此同時,2022年全國暑期檔票房達到92億元,較去年增長24%。目前全國有680家IMAX影院在正常營業中,營業率穩定在90%以上。為促進電影市場有序復甦,國家電影局擬在8月至10月持續開展2022年電影惠民消費季活動。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.